Discover why KRAS was historically labeled “undruggable,” how covalent KRAS G12C inhibitors like sotorasib and adagrasib overcame structural challenges, and what this breakthrough means for treating KRAS-mutant cancers such as NSCLC, colorectal, and pancreatic tumors.
Discover why KRAS became the iconic “undruggable” oncogene in cancer biology, how covalent KRASG12C inhibitors like sotorasib and adagrasib opened the door, and what’s next for targeting common KRAS mutations such as G12D and G12V in lung, pancreatic, and colorectal cancers.
Discover how KRAS evolved from an “undruggable” oncogene to a validated drug target. Learn how covalent KRASG12C inhibitors like sotorasib and adagrasib work, and explore emerging noncovalent strategies for targeting other KRAS mutations in lung, colorectal, and pancreatic cancer.